Girdin protein: A potential metastasis predictor associated with prognosis in lung cancer

Yang,Zhaoyang; Yang,Fang; Zhang,Yingli; Wang,Xin; Shi,Jiong; Wei,Hongjiao; Sun,Fengwei; Yu,Yan

doi:10.3892/etm.2018.5773

Girdin protein: A potential metastasis predictor associated with prognosis in lung cancer

Authors:
- Zhaoyang Yang
- Fang Yang
- Yingli Zhang
- Xin Wang
- Jiong Shi
- Hongjiao Wei
- Fengwei Sun
- Yan Yu
View Affiliations

Affiliations: Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang 150081, P.R. China, Department of Internal Medicine, Harbin Red Cross Center Hospital, Harbin, Heilongjiang 150081, P.R. China, Department of Pathology, Nanjing Drum Tower Hospital, Nanjing, Jiangsu 210000, P.R. China
Published online on: January 19, 2018 https://doi.org/10.3892/etm.2018.5773
Pages: 2837-2843
Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study explored the relationship between Girdin protein expression and the survival rate of patients with lung carcinoma. A total of 334 lung cancer specimens, 20 benign lung disease tissue sections and 24 fresh tissues from patients with lung carcinoma were analyzed by immunohistochemistry and western blotting. Girdin protein was expressed in 130/334 (38.93%) of the cases examined. Girdin protein expression was correlated with tumor/node/metastasis stage (P<0.001), lymph node metastasis (P=0.001), distant metastasis (P<0.001) and specimen sites (P=0.034). Girdin expression was also correlated with signal transducer and activator of transcription 3 (STAT3) expression (P<0.001). Patients with high Girdin and STAT3 expression had a significantly poorer prognosis compared with those with low/high, high/low or low/low expression (P<0.001). In summary, Girdin may be a prognostic marker of lung cancer and serve as a biomarker for metastasis.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
2	Marx V: Tracking metastasis and tricking cancer. Nature. 494:133–136. 2013. View Article : Google Scholar : PubMed/NCBI
3	Cairns RA, Khokha R and Hill RP: Molecular mechanisms of tumor invasion and metastasis: An integrated view. Curr Mol Med. 3:659–671. 2003. View Article : Google Scholar : PubMed/NCBI
4	Cetin K, Ettinger DS, Hei YJ and O'Malley CD: Survival by histologic subtype in stage IV nonsmall cell lung cancer based on data from the surveillance, Epidemiology and end results program. Clin Epidemiol. 3:139–148. 2011. View Article : Google Scholar : PubMed/NCBI
5	Yang Y, Ahn YH, Chen Y, Tan X, Guo L, Gibbons DL, Ungewiss C, Peng DH, Liu X, Lin SH, et al: ZEB1 sensitizes lung adenocarcinoma to metastasis suppression by PI3K antagonism. J Clin Invest. 124:2696–2708. 2014. View Article : Google Scholar : PubMed/NCBI
6	Enomoto A, Murakami H, Asai N, Morone N, Watanabe T, Kawai K, Murakumo Y, Usukura J, Kaibuchi K and Takahashi M: Akt/PKB regulates actin organization and cell motility via Girdin/APE. Dev Cell. 9:389–402. 2005. View Article : Google Scholar : PubMed/NCBI
7	Ohara K, Enomoto A, Kato T, Hashimoto T, Isotani-Sakakibara M, Asai N, Ishida-Takagishi M, Weng L, Nakayama M, Watanabe T, et al: Involvement of Girdin in the determination of cell polarity during cell migration. PLoS One. 7:e366812012. View Article : Google Scholar : PubMed/NCBI
8	Ghosh P, Tie J, Muranyi A, Singh S, Brunhoeber P, Leith K, Bowermaster R, Liao Z, Zhu Y, LaFleur B, et al: Girdin (GIV) expression as a prognostic marker of recurrence in mismatch repair-proficient stage II colon cancer. Clin Cancer Res. 22:3488–3498. 2016. View Article : Google Scholar : PubMed/NCBI
9	Liu C, Zhang Y, Xu H, Zhang R, Li H, Lu P and Jin F: Girdin protein: A new potential distant metastasis predictor of breast cancer. Med Oncol. 29:1554–1560. 2012. View Article : Google Scholar : PubMed/NCBI
10	Peng WT, Hu X, Yao L, Jiang YZ and Shao ZM: Elevated expression of Girdin in the nucleus indicates worse prognosis for patients with estrogen receptor-positive breast cancer. Ann Surg Oncol. 21 Suppl 4:S648–S656. 2014. View Article : Google Scholar : PubMed/NCBI
11	Gu F, Wang L, He J, Liu X, Zhang H, Li W, Fu L and Ma Y: Girdin, an actin-binding protein, is critical for migration, adhesion, and invasion of human glioblastoma cells. J Neurochem. 131:457–469. 2014. View Article : Google Scholar : PubMed/NCBI
12	Shibata T, Matsuo Y, Shamoto T, Hirokawa T, Tsuboi K, Takahashi H, Ishiguro H, Kimura M, Takeyama H and Inagaki H: Girdin, a regulator of cell motility, is a potential prognostic marker for esophageal squamous cell carcinoma. Oncol Rep. 29:2127–2132. 2013. View Article : Google Scholar : PubMed/NCBI
13	Song JY, Jiang P, Li N, Wang FH and Luo J: Clinical significance of Girdin expression detected by immunohistochemistry in non-small cell lung cancer. Oncol Lett. 7:337–341. 2014. View Article : Google Scholar : PubMed/NCBI
14	Buettner R, Mora LB and Jove R: Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res. 8:945–954. 2002.PubMed/NCBI
15	Lui GY, Kovacevic Z, V Menezes S, Kalinowski DS, Merlot AM, Sahni S and Richardson DR: Novel thiosemicarbazones regulate the signal transducer and activator of transcription3 (STAT3) pathway: Inhibition of constitutive and interleukin 6-induced activation by iron depletion. Mol Pharmacol. 87:543–560. 2015. View Article : Google Scholar : PubMed/NCBI
16	Dunkel Y, Ong A, Notani D, Mittal Y, Lam M, Mi X and Ghosh P: STAT3 protein up-regulates Gα-interacting vesicle-associated protein (GIV)/Girdin expression, and GIV enhances STAT3 activation in a positive feedback loop during wound healing and tumor invasion/metastasis. J Biol Chem. 287:41667–41683. 2012. View Article : Google Scholar : PubMed/NCBI
17	Pan B, Shen J, Cao J, Zhou Y, Shang L, Jin S, Cao S, Che D, Liu F and Yu Y: Interleukin-17 promotes angiogenesis by stimulating VEGF production of cancer cells viathe STAT3/GIV signaling pathway in non-small-cell lung cancer. Sci Rep. 5:160532015. View Article : Google Scholar : PubMed/NCBI
18	Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET and Carbone PP: Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol. 6:649–655. 1982. View Article : Google Scholar
19	Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V and Sobin L; International Association for the Study of Lung Cancer International Staging Committee, ; Participating Institutions, : The IASLC lung cancer staging project: Proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2:706–714. 2007. View Article : Google Scholar : PubMed/NCBI
20	Omori K, Asai M, Kuga D, Ushida K, Izuchi T, Mii S, Enomoto A, Asai N, Nagino M and Takahashi M: Girdin is phosphorylated on tyrosine 1798 when associated with structures required for migration. Biochem Biophys Res Commun. 485:934–940. 2015. View Article : Google Scholar
21	Garcia-Marcos M, Ghosh P and Farquhar MG: GIV/Girdin transmits signals from multiple receptors by triggering trimeric G protein activation. J Biol Chem. 290:6697–6704. 2015. View Article : Google Scholar : PubMed/NCBI
22	Garcia-Marcos M, Jung BH, Ear J, Cabrera B, Carethers JM and Ghosh P: Expression of GIV/Girdin, a metastasis-related protein, predicts patient survival in colon cancer. FASEB J. 25:590–599. 2011. View Article : Google Scholar : PubMed/NCBI
23	Wang A, Wang J, Sun L, Jin J, Ren H, Yang F, Diao K, Wei M and Mi X: Expression of tumor necrosis factor receptor-assicated factor 4 correlates with expression of Girdin and promotes nuclear translocation of Girdin in breast cancer. Mol Med Rep. 11:3635–3641. 2015. View Article : Google Scholar : PubMed/NCBI
24	Nishimae K, Tsunoda N, Yokoyama Y, Kokuryo T, Iwakoshi A, Takahashi M and Nagino M: The impact of Girdin expression on recurrence-free survival in patients with luminal-type breast cancer. Breast Cancer. 22:445–451. 2015. View Article : Google Scholar : PubMed/NCBI
25	Yue P, Zhang X, Paladino D, Sengupta B, Ahmad S, Holloway RW, Ingersoll SB and Turkson J: Hyperactive EGF receptor, Jaks and Stat3 signaling promote enhanced colony-forming ability, motility and migration of cisplatin-resistant ovarian cancer cells. Oncogene. 31:2309–2322. 2012. View Article : Google Scholar : PubMed/NCBI
26	Sun F, Zhang ZW, Tan EM, Lim ZLR, Li Y, Wang XC, Chua SE, Li J, Cheung E and Yong EL: Icaritin suppresses development of neuroendocrine differentiation of prostate cancer through inhibition of IL-6/STAT3 and Aurora kinase a pathways in TRAMP mice. Carcinogenesis. 37:701–711. 2016. View Article : Google Scholar : PubMed/NCBI
27	Hu JT, Li Y, Yu B, Gao GJ, Zhou T and Li S: Girdin/GIV is upregulated by cyclic tension, propagates mechanical signal transduction, and is required for the cellular proliferation and migration of MG-63 cells. Biochem Biophys Res Commun. 464:493–499. 2015. View Article : Google Scholar : PubMed/NCBI